Great! So let me get this right you think that the CEO sticking it to the common shareholders through dilution is laughable? Also you point out that the CEO has ample personal equity and access to non-toxic financing options but again has knowingly chosen to stick it to common shareholders? Further he has chosen to put zero personally into this venture showing exactly how confident he is in his own business model. Way to put it in perspective for everyone, thanks for that.
what are you talking about? no conventional lender will give him a dime so far
Tom has access to more financing than he would ever need.
right, that's why bvtk has 1 employee...good luck selling any cybersecurity solution with 1 employee...tom!
if he access to all this financing why is he a toxic financing junkie? 1/2500 split just 19 months ago??? from latest 10-Q: The Company valued the derivative liabilities at September 30, 2017, and March 31, 2017, at $12,428,028 and $1,645,015, respectively.
On August 1, 2017, Dr. Cellucci, as collateral security, pledged 111,884 shares of his Series C Preferred Stock to the convertible promissory notes issued to Carebourn on the following dates and amounts; February 8, 2016 $80,000, March 24, 2016, $19,000, June 3, 2016, $42,350, May 3, 2017, $124,775, June 9, 2017, $165,025 and June 23, 2017, $262,775. This pledge replaces the pledge dated March 23, 2016.
sound like a guy who "has access to more financing than he would ever need?"
News 
Market Data 
Discover 
